{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:23:22Z","timestamp":1778617402364,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44982-8","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:23:35Z","timestamp":1774329815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation between human expert macular fluid height assessment and fluid volume quantification in neovascular age-related macular degeneration"],"prefix":"10.1038","volume":"16","author":[{"given":"Stefan","family":"Steiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca S.","family":"Gerendas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor","family":"Deak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Leingang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadne","family":"Whitby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Bogunovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor S.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"44982_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70113-X","author":"RRA Bourne","year":"2013","unstructured":"Bourne, R. R. A. et al. Causes of vision loss worldwide, 1990-2010: A systematic analysis. Lancet. Glob. Health. https:\/\/doi.org\/10.1016\/S2214-109X(13)70113-X (2013).","journal-title":"Lancet. Glob. Health."},{"key":"44982_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-016-0063-5","author":"KL Pennington","year":"2016","unstructured":"Pennington, K. L. & DeAngelis, M. M. Epidemiology of age-related macular degeneration (AMD): Associations with cardiovascular disease phenotypes and lipid factors. Eye. Vis. https:\/\/doi.org\/10.1186\/s40662-016-0063-5 (2016).","journal-title":"Eye. Vis."},{"key":"44982_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1","author":"WL Wong","year":"2014","unstructured":"Wong, W. L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet. Glob. Health. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1 (2014).","journal-title":"Lancet. Glob. Health."},{"issue":"5","key":"44982_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide, R. F. et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127(5), 616\u2013636 (2020).","journal-title":"Ophthalmology"},{"key":"44982_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth, U. & Waldstein, S. M. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog. Retin. Eye. Res. 50, 1\u201324 (2016).","journal-title":"Prog. Retin. Eye. Res."},{"issue":"9","key":"44982_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth, U., Vogl, W. D., Jampol, L. M. & Bogunovi\u0107, H. Application of automated quantification of fluid volumes to anti\u2013VEGF therapy of neovascular age-related macular degeneration. Ophthalmology 127(9), 1211\u20131219 (2020).","journal-title":"Ophthalmology"},{"issue":"1","key":"44982_CR7","first-page":"57","volume":"125","author":"A Berta","year":"2017","unstructured":"Berta, A., Larsen, M. & Macfadden, W. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration results with ranibizumab from the TREND study. Ophthalmology 125(1), 57\u201365 (2017).","journal-title":"Ophthalmology"},{"issue":"5","key":"44982_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S. & Su\u00f1er, I. J. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular. Ophthalmology 120(5), 1046\u20131056 (2013).","journal-title":"Ophthalmology"},{"key":"44982_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017","author":"PU Dugel","year":"2020","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017 (2020).","journal-title":"Ophthalmology"},{"key":"44982_CR10","unstructured":"Pawloff, M., Bogunovic, H., Gruber, A., Michl, M., Riedl, S., Schmidt-Erfurth, U Systematic correlation of central subfield thickness with retinal fluid volumes quantified by deep learning in the major exudative macular diseases [Internet]. Available from: http:\/\/links.lww.com\/IAE\/"},{"key":"44982_CR11","first-page":"1","volume":"2023","author":"M Pawloff","year":"2022","unstructured":"Pawloff, M. et al. Performance of retinal fluid monitoring in OCT imaging by automated deep learning versus human expert grading in neovascular AMD. Eye (Basingstoke). 2023, 1\u20138 (2022).","journal-title":"Eye (Basingstoke)."},{"issue":"4","key":"44982_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","volume":"125","author":"T Schlegl","year":"2018","unstructured":"Schlegl, T. et al. Fully automated detection and quantification of macular fluid in OCT using deep learning. Ophthalmology 125(4), 549\u2013558. https:\/\/doi.org\/10.1016\/j.ophtha.2017.10.031 (2018).","journal-title":"Ophthalmology"},{"issue":"6","key":"44982_CR13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/bjophthalmol-2014-305573","volume":"99","author":"SM Waldstein","year":"2015","unstructured":"Waldstein, S. M., Gerendas, B. S., Montuoro, A., Simader, C. & Schmidt-Erfurth, U. Quantitative comparison of macular segmentation performance using identical retinal regions across multiple spectral-domain optical coherence tomography instruments. Br. J. Ophthalmol. 99(6), 794\u2013800 (2015).","journal-title":"Br. J. Ophthalmol."},{"issue":"10","key":"44982_CR14","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1167\/iovs.16-20201","volume":"58","author":"S Klimscha","year":"2017","unstructured":"Klimscha, S. et al. Spatial correspondence between intraretinal fluid, subretinal fluid, and pigment epithelial detachment in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 58(10), 4039\u20134048 (2017).","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"9","key":"44982_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/bjo.2007.115501","volume":"91","author":"SY Cohen","year":"2007","unstructured":"Cohen, S. Y. et al. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br. J. Ophthalmol. 91(9), 1173\u20131176 (2007).","journal-title":"Br. J. Ophthalmol."},{"key":"44982_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/00132578-200407000-00023","volume":"5","author":"TW Olsen","year":"2004","unstructured":"Olsen, T. W. et al. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Evid. Based Eye Care 5, 167\u2013169 (2004).","journal-title":"Evid. Based Eye Care"},{"key":"44982_CR17","unstructured":"Najeeb, H. B., Deak, G., Schmidt-erfurth, U., Gerendas, B.S. THE RAP STUDY, REPORT TWO the regional distribution of macular neovascularization type 3, a novel insight into its etiology [Internet]. Available from: http:\/\/journals.lww.com\/retinajournal"},{"issue":"7","key":"44982_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/bjo-2022-323014","volume":"108","author":"V Mares","year":"2024","unstructured":"Mares, V. et al. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. Br. J. Ophthalmol. 108(7), 971\u2013977 (2024).","journal-title":"Br. J. Ophthalmol."},{"issue":"5","key":"44982_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jcjo.2023.10.017","volume":"59","author":"GS Reiter","year":"2024","unstructured":"Reiter, G. S. et al. Long-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: Results from Fight Retinal Blindness!. Can. J. Ophthalmol. 59(5), 350\u2013357 (2024).","journal-title":"Can. J. Ophthalmol."},{"issue":"1","key":"44982_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40942-025-00695-0","volume":"11","author":"V Mares","year":"2025","unstructured":"Mares, V. et al. Automated fluid monitoring to optimize the follow-up of neovascular age-related macular degeneration patients in the Brazilian population. Int J Retina Vitreous. 11(1), 75 (2025).","journal-title":"Int J Retina Vitreous."},{"issue":"1","key":"44982_CR21","doi-asserted-by":"publisher","first-page":"32881","DOI":"10.1038\/s41598-025-17417-z","volume":"15","author":"P Fuchs","year":"2025","unstructured":"Fuchs, P. et al. Impact of AI-quantified fluid dynamics on visual outcomes over 5 years in patients with treatment-na\u00efve nAMD from the FRB! registry. Sci Rep. 15(1), 32881 (2025).","journal-title":"Sci Rep."},{"key":"44982_CR22","doi-asserted-by":"crossref","unstructured":"Mettu, P.S., Allingham, M.J., Cousins, S.W. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Vol. 82, Progress in retinal and eye research. Elsevier Ltd. 2021.","DOI":"10.1016\/j.preteyeres.2020.100906"},{"key":"44982_CR23","unstructured":"Heier, J.S., Lad, E.M., Holz, F.G., Rosenfeld, P.J., Guymer, R.H., Boyer, D. et al. Articles Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): Two multicentre, randomised, double-masked, sham-controlled, phase 3 trials [Internet]. Vol. 402, www.thelancet.com. 2023. Available from: www.thelancet.com"},{"issue":"10411","key":"44982_CR24","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani, A. M. et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. The Lancet. 402(10411), 1449\u20131458 (2023).","journal-title":"The Lancet."},{"issue":"1","key":"44982_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/bjophthalmol-2020-317416","volume":"106","author":"M Michl","year":"2022","unstructured":"Michl, M. et al. Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy. Br. J. Ophthalmol. 106(1), 113\u2013120 (2022).","journal-title":"Br. J. Ophthalmol."},{"issue":"9","key":"44982_CR26","doi-asserted-by":"publisher","first-page":"OCT14","DOI":"10.1167\/iovs.16-19969","volume":"57","author":"PJ Rosenfeld","year":"2016","unstructured":"Rosenfeld, P. J. Optical coherence tomography and the development of antiangiogenic therapies in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 57(9), OCT14-26 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"44982_CR27","first-page":"2983","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy, U. et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Basingstoke). 35(11), 2983\u20132990 (2021).","journal-title":"Eye (Basingstoke)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44982-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:03:44Z","timestamp":1778616224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44982-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44982"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44982-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5313889\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.W. is an employee of RetInSight and does not hold any equity or shares in the company. B.S.G. is a scientific consultant for Roche, Zeiss, Bayer, and Abbvie. G.S.R is a scientific consultant for Apellis, Bayer, Boehringer Ingelheim and Roche and received research funds from RetInSight. H.B. received research funds from Heidelberg Engineering and Apellis. O.L. is an employee of RetInSight and does not hold any equity or shares in the company. U.S.-E. is a scientific consultant for Apellis, Bayer, AbbVie, Medscape, Allergan, Roche, Boehringer, Aviceda, Annexon, Topcon, Alkeus and received research funds by Genentech, Kodiak, Novartis, RetInSight, Apellis Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study received approval from the Ethics Committee of the Medical University of Vienna. It was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"14793"}}